GMP-Bios-peptide-001
$780.00 – $7,800.00
Cat No.: GMP-Bios-peptide-001
Product Name: Tirzepatide TFA
Structural formula:
Tirzepatide TFA, the trifluoroacetic acid salt form of Tirzepatide. Tirzepatide, a new glucose-lowering therapy for diabetes, is called a “dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist”. Drug company Lilly released important results showing that this new therapy may be extremely effective for people with type 2 diabetes. Across three clinical trials, tirzepatide reduced A1C by an average of 2.5 percentage points and led to a weight loss of about 25 pounds.
| Product Name | Tirzepatide TFA |
|---|---|
| Brand name | NA (also known as LY3298176 TFA) |
| CAS No. | 2023788-19-2 |
| Formula | C227H349F3N48O70 |
| Biological Activity | Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. |
| Purity | Purity: ≥98% (HPLC) |
| Application | Therapeutic peptides drug benchmark or raw material for peptide drugs or peptide conjugation drugs discovery and development. |
| Predicted Molecular Mass | 4927.47 |
| Formulation | Powder |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Related products
biologics
biologics
biologics
biologics
biologics
biologics
biologics
biologics
